Bellevue Group Ag Inhibrx, Inc. Transaction History

Bellevue Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$14.5 - $38.0 $350,900 - $919,600	-24,200 Reduced 49.59%	24,600 $934,000
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $323,936 - $531,362	19,100 Added 64.31%	48,800 $1.27 Million
Q4 2022 Feb 14, 2023	SELL	$20.18 - $33.33 $278,484 - $459,954	-13,800 Reduced 31.72%	29,700 $731,000
Q3 2022 Nov 14, 2022	SELL	$11.58 - $24.73 $383,298 - $818,563	-33,100 Reduced 43.21%	43,500 $781,000
Q2 2022 Aug 11, 2022	BUY	$8.52 - $25.26 $229,188 - $679,494	26,900 Added 54.12%	76,600 $869,000

Q1 2022 May 13, 2022	SELL	$19.89 - $43.18 $15,912 - $34,544	-800 Reduced 1.58%	49,700 $1.11 Million
Q4 2021 Feb 10, 2022	BUY	$26.75 - $46.02 $1.35 Million - $2.32 Million	50,500 New	50,500 $2.21 Million

132

35.5M

64.8K

91.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.